Skip to main content
OXFORD BIODYNAMICS PLC logo

OXFORD BIODYNAMICS PLC — Investor Relations & Filings

Ticker · OBD ISIN · GB00BD5H8572 LEI · 2138005Y1TK258O5U928 IL Professional, scientific and technical activities
Open in API
Filings indexed 416 across all filing types
Latest filing 2020-03-02 Director's Dealing
Country GB United Kingdom
Listing IL OBD

About OXFORD BIODYNAMICS PLC

https://www.oxfordbiodynamics.com/

Oxford BioDynamics PLC is a global biotechnology company advancing personalized healthcare by developing and commercializing precision medicine tests. The company's proprietary EpiSwitch® platform utilizes 3D genomics and epigenetic biomarkers to create diagnostic solutions for life-changing diseases, with a focus on oncology. Its portfolio of clinical tests includes the EpiSwitch® PSE, a blood test that assesses the likelihood of prostate cancer with high accuracy to help reduce unnecessary biopsies, and the EpiSwitch® CiRT, a test designed to predict a patient's therapeutic response to Immune Checkpoint Inhibitor cancer therapies. The platform enables the translation of 3D genome regulation into clinical applications for precision medicine at scale.

Recent filings

Filing Released Lang Actions
Correction - PDMR Dealing
Director's Dealing Classification · 98% confidence The document is explicitly identified as an 'RNS Number' announcement from the London Stock Exchange. The content details a 'Correction - PDMR Dealing' (Persons Discharging Managerial Responsibilities Dealing) concerning the purchase of Ordinary Shares by a Non-Executive Director (Stephen Diggle) and associated funds. This type of insider transaction report, mandated by regulations like the EU Market Abuse Regulation, falls under the category of Director's Dealing (DIRS). Although it is distributed via RNS, the specific content points directly to DIRS, which is more specific than the general RNS fallback.
2020-03-02 English
PDMR Dealing
Director's Dealing Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly states it is providing 'Additional information' via RNS. The content details a transaction involving a Non-Executive Director (Stephen Diggle) purchasing company shares, which falls under insider dealing or director's dealing regulations (PDMR Dealing). This type of mandatory disclosure regarding executive share transactions is specifically covered by the 'Director's Dealing' category (DIRS). Although it is distributed via RNS, the specific nature of the content points directly to DIRS, which is more specific than the general RNS fallback.
2020-02-28 English
PDMR Dealing
Director's Dealing Classification · 100% confidence The document is identified by the 'RNS Number' header and contains a notification regarding a transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically a Non-Executive Director (Stephen Diggle), involving the acquisition of Ordinary Shares. This type of insider transaction report, detailing director dealings, directly corresponds to the 'Director's Dealing' category. The presence of the RNS number and the nature of the content confirm it is a regulatory announcement, but the specific content points precisely to DIRS, which takes precedence over the general RNS fallback. The document length (4318 chars) is not indicative of a full report, but the content is specific enough to classify it definitively.
2020-02-26 English
OBD to present at BioTech Pharma Summit
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's news service (RNS). The content announces that Oxford BioDynamics Plc will be presenting data at an external industry summit ('BioTech Pharma Summit: Liquid Biopsy 2020'). This is not a formal financial report (like 10-K or IR), nor is it a management change (MANG), dividend notice (DIV), or earnings release (ER). It is a general announcement regarding company activity and participation in an industry event, which fits best under the general regulatory announcement category, RNS, as it is explicitly distributed through the RNS system.
2020-02-20 English
Second Price Monitoring Extn
Regulatory Filings Classification · 99% confidence The document is very short (1507 characters) and contains the header 'RNS Number : 9733C'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. This is a general regulatory announcement concerning market operations rather than a specific financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement provided via RNS, and it doesn't fit into the other specific categories (like DIRS, DIV, or MANG), the most appropriate classification is the general Regulatory Filings category (RNS).
2020-02-13 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1490 characters) and contains an 'RNS Number' header, indicating it is a regulatory news service announcement from the London Stock Exchange. The content specifically discusses a 'Price Monitoring Extension' for a security, which is a routine operational update related to trading mechanisms, not a core financial report (like 10-K, IR, or ER) or a specific corporate action (like DIV or SHA). Since it is a general regulatory announcement that doesn't fit the highly specific categories (AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A, RPA, SHA, POS), the most appropriate classification is the general fallback category for miscellaneous regulatory filings, which is 'RNS'.
2020-02-13 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.